Medlab Clinical (MDC.AX) Osake Kurssi
Medlab Clinical Kurssi
Medlab Clinicaln liikevaihto on supistunut 30,9 % vuodessa viimeisten 10 vuoden aikana 14 600,00 AUD:een. Medlab Clinicaln nettomarginaali on nyt −14 593,2 %, laskenut −458,2 %:sta muutama vuosi sitten.
Medlab Clinical osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Medlab Clinical liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Medlab Clinical -osakkeesta
The business model of Medlab Clinical Ltd is focused on innovative medical research and the development of therapeutic formulations. As a leading Australian biotech company, Medlab Clinical specializes in developing and commercializing nutraceuticals, pharmaceuticals, and diagnostic tools to improve patient outcomes. Medlab Clinical aims to leverage its expertise in advanced delivery platforms and nutraceutical products to address various health conditions, including pain management, depression, and chronic diseases. By prioritizing research-backed solutions and strategic collaborations, Medlab Clinical aims to transform healthcare through evidence-based treatments and personalized medicine.
Medlab Clinical Ltd is primarily active in the healthcare and biotechnology industries.
The main competitors of Medlab Clinical Ltd in the market include companies such as Sonic Healthcare Limited, Healius Limited, Integral Diagnostics Limited, and Capitol Health Limited. These companies also operate in the medical diagnostics and healthcare industry, offering similar services and solutions. Despite facing competition, Medlab Clinical Ltd has established a strong presence and reputation through its innovative offerings, research collaborations, and dedication to improving patient outcomes.
Medlab Clinical Ltd is an Australian biotechnology company specializing in developing and commercializing novel therapeutic products for chronic diseases. Established in 2012, Medlab Clinical has rapidly emerged as a leader in the medical research and development sector. With a strong focus on scientific innovation, the company aims to improve patient outcomes through its advanced drug delivery systems and targeted treatments. Medlab Clinical has garnered recognition for its cutting-edge medical advancements, including patented NanoCelle™ technology. With a commitment to research excellence and a dedicated team of experts, Medlab Clinical continues to revolutionize the field of biotechnology and pave the way for groundbreaking medical solutions.
Some significant milestones achieved by Medlab Clinical Ltd include the successful completion of a Phase 2 trial for their lead drug candidate, NRGBiotic, for managing depression symptoms. The company has also received various regulatory approvals and successfully launched several products, including Nanabis, a cannabis-based product for pain management. Medlab Clinical Ltd has established collaborations with prestigious research institutions and universities worldwide, contributing to advancements in medical research. The company continues to expand its global reach, with strategic partnerships and acquisitions, positioning itself as an innovative leader in the field of personalized medicine and nutraceuticals.
Medlab Clinical Ltd is primarily present in Australia and New Zealand.
Medlab Clinical Ltd is a renowned company that upholds its core values and corporate philosophy with utmost dedication. The company firmly believes in promoting innovative and evidence-based medical research to improve patient outcomes. With a focus on scientifically driven products, Medlab Clinical Ltd strives to develop and deliver advanced therapeutic solutions in the field of medical science. The company values integrity, commitment, and excellence, as it strives to provide cutting-edge diagnostics and personalized medicine. Medlab Clinical Ltd's dedication to upholding these values has made it a trusted name in the healthcare industry, offering high-quality solutions for better patient care.
5 analyytikkoa arvioi tällä hetkellä Medlab Clinical-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Medlab Clinical-yhtiöltä 17,90 M AUD liikevaihtoa ja −3,52 AUD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Medlab Clinical-osake noteerataan hintaan 4,09 EUR (6,60 AUD).
Medlab Clinical-osake (MDC.AX) on listattuna 1 pörssissä, muun muassa: ASX (MDC.AX).
Medlab Clinical Ltd is an Australian company specializing in the development and provision of clinical diagnostic solutions for medical professionals. The company operates in three main divisions: diagnostic services, biotechnology, and research and development. The diagnostic services provide a variety of laboratory tests for medical conditions, including hormone tests, immune tests, and microbiology tests. The biotechnology division focuses on developing groundbreaking drugs and therapies for serious diseases such as inflammation and cancer. The research and development division invests in innovative technologies and products to meet the needs of medical professionals and their patients. Medlab Clinical offers a wide range of products and services, including probiotics for digestive and gut health, skin-friendly nutraceuticals, and blood tests for various medical conditions. The company's strong business model is based on innovation, research, and customer service. It aims to maintain its reputation as a leading provider of clinical diagnostic solutions and biotechnological developments through continuous innovation and excellent customer satisfaction.
odotettu liikevaihto Medlab Clinical on 17,90 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Medlab Clinical on −8,05 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Medlab Clinical:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Medlab Clinical-osakkeen arvostusta.
Medlab Clinical:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,84. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Medlab Clinical-osakkeen arvostuskennuslukuna.
Medlab Clinical:n Eulpool-laatuscore on 2/10.
Medlab Clinical:n ISIN on AU000000MDC8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Medlab Clinical:n WKN on A14R7W. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Medlab Clinical:n ticker on MDC.AX. Tämä pörssinoteeraus käytetään Medlab Clinical-osakkeiden kauppaan pörssissä.
Medlab Clinical osake
Medlab Clinical vertaisryhmä
Medlab Clinical Ticker
Medlab Clinical FIGI
Kaikki tunnusluvut ja syvällinen analyysi Medlab Clinical:sta
Meidän osakeanalyysimme Medlab Clinical-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Medlab Clinical:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: